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• The plan should include an executive overview, introduction to the management team, market and
competitive analyses, value proposition, operating plan, financial projections, and potential risks.
• The plan should be concise, well written, and dynamic. Details behind key assumptions should be
included.
• Common business plan pitfalls include focusing only on the product without framing it in the context
of the consumers/patients, the market dynamics, and the ecosystem in which it will be launched, as
well as giving financials that are too aggressive and precise given the stage the company is in.
• New founders should consider engaging experts to help test assumptions as they develop the key parts
of the business plan, including the financial projections.
• Many of the same concepts for writing a business plan for a startup apply to creating a business plan for
a new clinical program or expanding operations within a health system.
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Summary 
● The business plan is an important tool for raising capital, finding strategic partners, recruit-
ing, and providing an internal guide on how to drive a company’s growth. 
● The plan should include an executive overview, introduction to the management team, 
market and competitive analyses, value proposition, operating plan, financial projections, 
and potential risks.  
● The plan should be concise, well written, and dynamic. Details behind key assumptions 
should be included. 
● Common business plan pitfalls include focusing only on the product without framing it in 
the context of the consumers/patients, the market dynamics, and the ecosystem in which it 
will be launched, as well as giving financials that are too aggressive and precise given the 
stage the company is in. 
● New founders should consider engaging experts to help test assumptions as they develop 
the key parts of the business plan, including the financial projections.  
● Many of the same concepts for writing a business plan for a startup apply to creating a 
business plan for a new clinical program or expanding operations within a health system. 
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Introduction 
Building a life science startup is a long and complex endeavor, and the skills required are very 
different from the knowledge and training that academic scientists undergo. The process of devel-
oping a business plan ensures the team has tested their vision/strategy, and the plan can be used as 
a roadmap to guide their operations. It also serves as an important communication document when 
seeking investment in the business. Topics familiar to experienced grant writers—such as the 
significance, innovation, and approach topics from National Institutes of Health (NIH) grant 
applications—are relevant and necessary for framing the business plan. The plan also helps to keep 
the management team accountable, but sage entrepreneurs will recognize that they will often have 
to revise the original plan over time, based on clinical trial results, regulatory milestones, and 
market changes. There are several kinds of business plans, generally described as either one-page 
plans (business model canvas or lean launchpad) and traditional, full-length plans. While one-page 
business plans are a useful and simple tool for rapid, early iteration, the startup team will ultimately 
have to write a more detailed plan to secure funding (“Business Model Canvas”; Osterwalder and 
Pigneur). In this chapter, we focus on the later and will outline the key elements of a full-length 
biomedical business plan, highlight the pitfalls to avoid, and provide potential resources for new 
founders to get their plans started.   
 
It is important to note that developing a sound business plan is also highly relevant for supporting 
smaller-scale clinical programs, operational investments, and intrapreneurship efforts (see the 
chapter on "Intrapreneurship: Strategic Approaches for Managing Disruptive Innovation in Your 
Clinical and Research Projects"). Please see the section at the end of the chapter that outlines the 
key differences for these types of business plans. 
Key Elements of a Business Plan  
A) Executive summary 
The executive summary is a one to four page overview of the existing problem/need in the market 
and how the new product or service has a unique value proposition that addresses that need 
(Markowitz). It is the reader’s first impression of the business, and investors often read only the 
summary, so it is important for it to be compelling (Figure 1). Consider it a concise but more 
formal “elevator pitch” that highlights what the company is and why the product or service will 
win in the market (Cohen). The remainder of the executive summary should include the short- and 
long-term goals, key points in the strategic plan, the business model, summary of financial projec-
tions, and information about employees and location (Valentin). 
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Figure 1. Elements in an Executive Summary. 
 
 
 
B) Management team and advisors  
This section introduces the management team, their backgrounds, and how their expertise aligns 
with their particular roles in the business. In addition to the management team, there should be a 
Scientific Advisory Board (SAB), which helps to guide technology decisions, and a Board of Di-
rectors (BoD) which helps to guide all key decisions for the company. SAB and BoD members 
should be chosen based on their ability to provide industry knowledge and key industry connec-
tions that can help the company grow. Having industry experts involved in the company gives 
assurance—especially to investors—that the technology and operations have been vetted and are 
supported by those who know the market well.  
 
C) Market Overview   
This section should describe the overall landscape of the market, including the size of the market, 
key segments, historical and expected market growth, and key drivers or trends that may impact 
the problem the startup is trying to solve.  
 
Market size estimates for life science businesses often include the incidence and prevalence of the 
disease/condition related to the problem, the estimated medical cost burden—in the U.S. or glob-
ally—associated with the condition, and the estimated cost for the consumer/patient with the 
current available solutions (see the chapter “Conducting Insightful Market Research”). It may be 
useful to describe any relevant preclinical and clinical data that support why this problem exists 
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and highlight the market need. While a large market size is usually viewed positively, it is 
important that the information provided focus on the market size relevant to the startup’s specific 
solution. For example, a business plan for an intervention to treat prescription opioid addiction 
should include details about the global market for opioid drugs, the most recent trends and the 
expected growth rate of prescribed opioid use and abuse, the morbidity and mortality associated 
with opioid abuse, and the estimated annual cost for the treatment of opioid abuse and addiction, 
including the subsequent medical and mental health costs. To demonstrate market size in this ex-
ample, estimates would include the number of emergency department visits, hospitalizations, 
intensive care unit admissions, and procedures for overdose or opioid abuse–related complications, 
as well as the current number, length, and cost of drug rehabilitation admissions.  
 
In terms of the current market, it is useful to describe how the market is divided into custom-
er/patient segments, which may be by geographic region, demographics, psychographic, or 
customer type (in healthcare, this might be pediatric vs. adult, or inpatient hospital vs. outpatient 
setting), among others, who are using a certain type of product/service. In the above example of 
the opioid market, there is segmentation in application (pain relief, anesthesia, cough suppression, 
diarrhea suppression, or treating addiction) and by geography (North America, Europe, Asia-
Pacific, South America, and the Middle East/Africa, which can be further broken down by key 
countries), which can then be mapped to the types of opioid products with different mechanisms 
of action (for example, short acting vs. long acting opioids). If the market has clear 
customer/market segments, there are likely different drivers of demand in each of them, which 
should be well understood since the startup will want to provide product/service offerings that 
meet the needs of those segments. Describing the market structure, how this market is segmented, 
and projected growth rate of target segments will make it easier to determine which segments are 
the most valuable and to describe how they will be targeted. 
 
As the market data are outlined, it is important to tie back to the product/service offering and how 
it is uniquely positioned to fulfill the unmet need(s) within the particular target markets (see the 
chapter “Identifying Unmet Needs: Problems that Need Solutions”). Use market research, eco-
nomic trends, and even patient and provider behaviors, if appropriate, to determine what sector(s) 
of the market the product fits best. Understand the needs of patients, providers, and hospitals and 
why the startup’s strategy will meet these needs, in order to better prepare the marketing plan for 
the product. Moreover, it is important to highlight the attributes of the market that support the 
offering, such as a large addressable market size, rapid growth in the market segment(s) of interest, 
and/or the level of competition in these segments. These are dimensions that are critical to stake-
holders when they evaluate the business plan.  
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D) Competitive Landscape 
The problem the startup is seeking to solve is one that multiple incumbents are likely already 
addressing today, either directly or indirectly. This section should provide an overview of the 
current offerings in the market, where they fall short, and how the new offering fills a current gap 
in the market. In the above sections, the problem should have been outlined and framed in a way 
that there would be critical dimensions that matter to stakeholders (patients, physicians, providers, 
payers). It would be helpful to describe how these competitive offerings compare across these 
dimensions, which sets up the next section on value proposition.  
 
Understanding the competitors’ product and services, market share, current and past strategies, 
strengths and weaknesses, the threats they pose to the startup, and the opportunities they make 
available are integral to a thorough and useful analysis of the competition. This is not just an ex-
ercise to learn about other businesses; it will also help identify the strengths and weakness of the 
startup’s business strategy (see the chapter “Startup Company Formation and Management”). 
Consider developing a basic profile of each of the current direct competitors in the market with 
these characteristics and include it in the Appendix. 
 
Typical sources of information are company websites and marketing materials (Hisrich et 
al.).  Academic libraries can also provide a wealth of information through their subscriptions. 
Other helpful strategies include browsing media outlets for press releases and public relations in-
formation, social media, and former customers’ testimonials on how they perceive the competition.  
 
E) Value Proposition 
Building off the market need and competitive landscape analysis, the value proposition of the 
startup’s solution should be articulated in this next section. Against the dimensions that matter to 
stakeholders, this section of the plan should describe how the new solution will outperform the 
competition. The value proposition statement is a key way to succinctly demonstrate the measur-
able benefit that the patient or provider would get from the new product or service, and why 
patients or health care providers would choose it over existing solutions. Money savings, time, and 
convenience add to the value of a product. It is important to explain this in a way that can be 
understood by both scientific and nonscientific audiences. Describe the product/service without 
revealing too much proprietary information since the business plan may be distributed beyond the 
intended recipients. 
 
The research results that led to the development of the new product should be shared. This may 
include pilot data, preclinical/animal model studies, and/or clinical trials, depending on what stage 
of testing the product has undergone (see the chapter “Pre-Clinical Animal Models”). Provide pre-
liminary data and reference specific publications that support the product. In addition, any results 
of prototype testing should be included. 
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In the life sciences realm, even if the product solution meets the needs of a patient, ensuring that 
it fits into the medical ecosystem is imperative. Understanding the infrastructure of a hospital, 
including the physicians, the administrators, the insurance payers, and whether or not the new 
offering will improve a patient’s quality of life or improve outcomes such that payers will reim-
burse the startup for its technology is critical to success. It is also important to articulate (if 
applicable) whether or not the offering can be dropped into existing treatment algorithms/processes 
or if changes will need to be made to how work is done to adopt the solution. If a lot of re-training 
or adjustments around the rest of the ecosystem are required, the value proposition will be more 
challenging since a lot of changes will need to be made to adopt the solution.   
 
F) Operating Plan 
With the market and competitive landscape outlined, and the company’s value proposition defined, 
this section should describe how the company will execute to capitalize on the opportunity. The 
operating plan should begin with a thorough explanation of the business model—how the company 
will work successfully with clients, suppliers, manufacturers, and partners to generate profit. 
Include here the organizational structure of the company. Next, describe all critical technical, 
regulatory, and strategic milestones. Finally, outline any functional details about daily execution 
(Friend and Zehle). 
 
There are numerous business models, and any one industry may have several examples of success-
ful companies using different approaches. For example, is the company going to adopt an 
integrator model, where they will build out everything needed to launch the offering, or will they 
adopt an orchestrator model, where they will partner with people for certain core competencies 
(e.g., manufacturers) to bring the solution to market? The operating plan should describe the se-
lected model and explain why it is preferable to alternatives. Referencing the leading players 
highlighted in the competitive landscape section and contrasting against their business models may 
also be helpful.  
 
Healthcare businesses must deal with reimbursement, fee schedules, billing systems, managed care 
contracts, and licensing, along with operational issues. The operating plan must address how these 
challenges will be handled and how the company will get paid, either through insurance reim-
bursement, by employers, on a fee-for-service basis, or directly by consumer payments. The long 
sales cycle in most health care businesses is particularly challenging for startups and requires keen 
long-term planning. 
 
Reimbursement by third-party payers to hospitals and physicians is one of the determinants in 
whether or not a product will ultimately make it to market, whether it will be used by healthcare 
providers and patients, and how accessible the product will be. For most technology in healthcare, 
the payers account for most of the purchasing. Understanding the payers’ reimbursement process, 
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their reimbursement terms, their method for determining the amount to be paid to the provider, 
and their policy on out-of-pocket cost sharing with the patients is integral as the reimbursement 
method will impact return on investment for the business (see the chapter “Reimbursement Strat-
egies and CPT Codes for Device Development”). 
 
After establishing the business model, it is important to provide an overview of the significant 
milestones the company foresees. Include any remaining technical development goals, any regu-
latory approvals the company will face, and other strategic imperatives, such as licenses to related 
technology, critical partnerships, or protecting intellectual property. Biotechnology and biomedi-
cal devices may also need to go through extensive regulatory and legal processes before 
approval. These processes are outlined elsewhere in this textbook (see the chapter “FDA Device 
Regulation: 510(k), PMA” and, “FDA Drug Regulation: Investigational New Drug Applications”).  
 
Each of these milestones should include a description of the task, due date, budget, and responsible 
person. Due dates and budgets should be ranged since it is difficult to have 100% clarity; mile-
stones function as the management team’s commitment to investors, and the company’s ability to 
complete these goals will be assessed.  
 
Young businesses should also provide details about the market entry strategy to penetrate the 
targeted market effectively and to reach revenue and profit expectations. To develop this strategy, 
engaging with and understanding the ecosystem early on can help improve the design of the new 
offering and ensure that the solution can be reimbursed. Ideally, during this process one should 
meet with representatives across the ecosystem to understand what they care about and what the 
startup will need to deliver in order for them to embrace the new offering.  
 
The technical side of the operating plan should include tactical steps and a timeline for implement-
ing the plan and making the business operational. As a reference point, mention what has been 
done thus far. Explain how the business will operate, describing the current production process but 
also the planned process once the company is at scale. Include high-level details about labor, 
materials, technology, facilities, equipment, manufacturing processes, distribution plan, supply 
chain, and quality-control measures.  
 
G) Financial Projections 
In this section, the team must articulate the financials of the company and show that they have a 
solid understanding of their expenses, future revenue, and the projected timeline for achieving 
revenue goals. There will be many assumptions that go into these estimates, so it is important to 
provide ranges and to explain the assumptions behind the projections. Potential investors will re-
view them to gauge the robustness of an entrepreneur’s understanding of the challenges that lie 
ahead.  
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A startup’s financial statements should detail the anticipated financial performance over time (for 
example: expenses, assets, liabilities, and working capital). Since the financial performance of the 
startup is dependent on future events (e.g., regulatory approvals or clinical trial partnerships), the 
financial projections will likely need to be in the format of a ‘pro forma’ budget, which projects 
future revenues and expenses based on a set of assumptions. Projections of financial statements 
should go far enough into the future to help readers see where the business can go when it matures 
or reaches an exit point. Outlined below are the three major parts of the financial plan (Kolchinsky; 
Friend and Zehle).  
 
1) The income statement shows the revenue, expenses, and profit for the business over a specific 
time period. If there are multiple sources of revenue, these may be itemized for future compar-
isons over time. Early on in the business development, this may be generated monthly and 
eventually quarterly or annually. An income statement showing earnings before interest, taxes, 
depreciation, and amortization (EBITDA) acts as a frequent proxy for a cash flow statement. 
 
2) A statement of cash flow projections shows what the company expects to bring in and how 
much it will be spending each month. This includes tracking the cash revenues and cash dis-
bursements for the month, and reconciling these two against the opening balance from the 
previous month. It is important to demonstrate that the startup can adhere to a budget and not 
overspend consistently. Thus, conservative estimates are preferred; this will increase the level 
of expenses, but the company should be able to justify why those expenses are needed. Addi-
tionally, the statement should show how much working capital the startup needs to pay the 
bills early on, and how long it will take to have a positive cash flow (bringing in more money 
than the company is spending). By estimating conservatively, the team can ensure that the 
company will have enough financial support (i.e., runway) to achieve the milestones without 
falling short of cash and going bankrupt. 
 
3) The balance sheet highlights any major working capital requirements and includes assets, lia-
bilities, and equity. Rather than showing trends, the balance sheet reflects these as of a set date. 
 
The additional components of the financial plan detail how the company expects to make money 
selling the product. These include:  
● the cost of the product, what factors go into the unit cost, and the plans for bringing these 
costs down when the company is at scale;  
● cost estimates for equipment, facilities, inventory, and day-to-day operations, including 
salaries; 
● the price the company expects to receive for the product and why it is achievable, especially 
in the context of reimbursement. 
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Due to the long process of taking a product to market in healthcare businesses, there should be a 
section in the financial plan about the capital required for the various regulatory milestones. As 
outlined in the operating plan, all product development, technical, and regulatory milestones would 
come with an estimated budget and timeframe for completion. Included in this is the cost of the 
Food and Drug Administration’s drug review process—a major consideration in the financial pro-
jections for life science startups. From preclinical research to the Investigational New Drug 
application, to clinical trials, to the New Drug Application submission and review, this process is 
expensive and takes many years to complete. How far along a product is in this process will factor 
greatly into how much money will be necessary to complete Phase 1, 2, and/or 3 trials, as well as 
the subsequent regulatory requirements. 
 
Clinical trials can incur substantial costs beyond distributing the study drug/device and the asso-
ciated study procedures. Site costs, fees for storage, technology solutions, and safety monitoring, 
core lab fees, and study staff salaries—for scientists, physicians, project managers, data managers, 
research coordinators, biostatisticians, and site management, including regulatory visits and 
investigator meetings—all must be budgeted into the cost of each phase, and the timeline to 
complete the data collection should be considered. In addition, up to 30% of any grant funding 
may need to go toward administrative overhead to carry out the study, if implemented at an 
academic medical center. In some cases, academic entrepreneurs can establish sponsored research 
agreements that allow components of the preclinical or clinical research to occur at their university 
(see chapters on “Post Alliance Agreements and Sponsored Research Agreements” and “Under-
standing Conflict of Interest for Academic Entrepreneurs”). As mentioned earlier, many of these 
projections may be pro forma because they will rely on the achievement of other milestones prior 
to implementation. 
 
H) Risks/Anticipated Problems  
All business plans should include a section on anticipated risks/problems and potential alternative 
strategies. This can demonstrate to investors that the entrepreneur has thought through potential 
challenges and has plans to either prevent them from occurring, or backup plans to mitigate the 
consequences. Generally speaking, a balanced approach is helpful here—not hiding or obfuscating 
major challenges, especially those that have befallen other companies, but at the same time not 
overwhelming the reader with negativity. At the very least, this can be a thought exercise for the 
startup and may identify issues that had not previously been considered. While a business plan is 
not a legal document or binding contract, intentional distortion of facts can come back to haunt a 
company. 
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Business Plans for Clinical or Operational Programs 
There will be many situations where an idea is not yet at the stage of becoming a company, but 
requires investment to drive growth or sustain operations. Examples include developing a new 
clinical program or service (e.g., a novel surveillance protocol postsurgical intervention that will 
result in diagnostic testing revenue) or expanding operations (e.g., building a new facility to treat 
patients who have an eating disorder). These situations also call for business plans in order to 
garner support and investment—in this case, the investment would be coming internally from the 
health system or institution rather than outside investors. 
 
The key components of these business plans are executive summary, background, proposal de-
scription, market and competitive analyses, operating plan, metrics for success, financial 
projections, and potential risks. Many of the same concepts from earlier apply, but the key 
differences include: 1) the business plan should specify the dollar amount of the resources needed 
to make the plan operational; and 2) the proposal description, operating plan, financial projections, 
and risks should take into account the impact of the plan on the existing operations of the system.  
 
As mentioned earlier, most health systems will have internal strategy and finance teams, which are 
helpful resources for developing business plans and should be consulted early on to help with the 
financial projections as well as the anticipated system impacts of the plan. The remainder of this 
section outlines each part of the business plan and focuses on the key differences from a startup 
business plan. 
Executive summary: In addition to the points covered in the startup executive summary, the exec-
utive summary for a new program/service/facility should include the “ask”—what resources (e.g., 
capital, new full-time employees, or other operating expenses) are being requested to support the 
new program. The executive summary should also state the expected financial return on the 
investment from the perspective of the institution (usually in terms of annual steady-state 
contribution margin or total incremental contribution margin over a period of time, usually seven 
years). 
 
Background: This section should describe the current state of operations. If the authors are pro-
posing a new clinical program, for example, they should describe the patient population being 
addressed, how they are currently being served, and the current volumes. It should also describe 
the limitations of the current state, the unmet need, and what factors necessitate a new solution.  
 
Proposal description: The authors should describe what new program/service/facility is being 
proposed, and how it addresses the current challenges. This section should also describe how the 
proposal will lead to growth—will the program reach a new patient population not previously 
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served? Have a greater geographic reach? Result in greater utilization of other services at the in-
stitution? This is also an appropriate place to describe other benefits of the plan, including 
improved quality, safety, patient experience, efficient resource utilization, etc. It is important for 
this section to align with the institution’s priorities. 
 
Market and competitive analyses: This section should look very much the same as described above 
in the startup business plan. 
 
Operating plan: This section should build on the proposal description and go into more technical 
detail. Details should include how the program will be staffed, what type of services will be deliv-
ered, where they will be delivered, hours of operation, pricing and reimbursement, and what the 
impact will be on downstream services and the rest of the institution. Thus, it requires a detailed 
understanding of how the institution currently operates, so the new proposal can realistically be 
integrated without excessive disruptions to operant workflow. 
 
Metrics for success: The authors should list two–three measurable metrics that will show the 
success of the program. These can include volume, financial, patient/staff satisfaction, or other 
related metrics. Ideally, there should be targets for each metric (e.g., “increase volume by 10% 
above baseline by year 3”). For plans where measurable impact will not be realized until several 
years out, milestone-based targets are also acceptable as near-term goals (e.g., “achieve regulatory 
approval by X date”). It is preferable that these metrics be ones that the institution already moni-
tors, thus enhancing alignment with current priorities and facilitating the ability to add this new 
project. In some cases, though, it may be necessary to develop new metrics, which should be done 
in consultation with the institution’s leadership. 
 
Financial projections: This section should include all components outlined above, with the excep-
tion of a balance sheet, since the plan is only describing a subset of operations within a larger 
system. For the pro forma income statement, it is useful to show multiple views: a base case view 
(if applicable), which shows current operations of the program/facility; an incremental view, which 
just shows the incremental revenue and expenses associated with the proposed plan; and a strategic 
view, which is the addition of the base case and incremental. It is also highly recommended to 
have a separate section outlining the assumptions used to develop the financial projections (e.g., 
data source, patient population, growth projections, operational start date and ramp-up speed). As 
these business plans are usually in the context of a large academic institution, it is helpful for 
planning purposes for the financial statements to specify the organizational entity to which the 
projected revenues and expenses will accrue (e.g., Hospital vs. Practice Plan vs. Research). 
 
Risks and mitigation: This section should look very much the same as described above in the 
startup business plan. In addition, the plan should consider potential risks/negative impacts to other 
parts of the institution. For example, if the plan proposes to build a new facility in a suburban 
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location, will it potentially cannibalize volume from the main location, and if so, what is the plan 
to mitigate revenue loss?  
 
The same tips on business plan writing apply here. Since clinical and operational programs need 
to function within the environment of an existing system, socializing the plan early and often is 
especially critical for gaining support, both for funding the plan and for implementing it. In some 
cases, this may involve obtaining regulatory approval from internal institutional entities, such as 
the institutional review board (IRB), legal counsel, or information services (especially if infor-
mation protected under the Health Insurance Portability and Accountability Act (HIPAA) is 
involved). Factoring time for these approvals is crucial.  
External Resources  
In academic entrepreneurship, there are a host of extra challenges that must be considered, includ-
ing who owns the intellectual property, technology transfer agreements, regulatory procedures, 
and conflict of interest, among others (Kolchinsky). At the same time, being part of an academic 
institution provides many resources not available to non-academic entrepreneurs, including 
business planning, legal, and funding support. Networking and taking advantage of other schools 
within the academic system who have experts in these fields will improve the entrepreneur’s 
knowledge, especially when entrepreneurship is not one’s first career or when this is one’s first 
experience with developing a product. This can be particularly valuable when estimating costs 
related to preclinical and clinical research. Many academic centers have clinical research offices 
that have pre-populated budget templates, which can help to ensure that all aspects of the clinical 
trial are adequately budgeted. Most academic systems also have corporate Strategy and Finance 
teams that can help with business analyses as well, such as market/competitive dynamics and pro-
jecting future demand (whether that be in terms of patient volume, demand for the product, etc.). 
In addition, university libraries may provide online access to publications and market research 
related to the product and the industry. For specific tasks, such as preparing an exit strategy that 
involves an initial public offering (IPO), extensive external legal and financial consultations are 
generally required.  
Tips on Business Plan Writing 
Remember that a business plan is dynamic, changing with the growth of the company and as the 
company pivots due to unexpected challenges or market trends. The plan should be comprehen-
sive, and key points, data, and strategies should be consistent throughout. Be mindful of including 
important details without going into excessive minutiae. Lastly, this is a professional document, 
and it can be the first and lasting impression of the company on potential investors, so appearance 
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matters. To this end, recruit trusted editorial support to make sure the plan is consistent from 
beginning to end and to check for correct spelling, grammar, and formatting. 
Conclusion  
Writing a business plan is a process. It requires brainstorming, researching, prewriting, drafting, 
revising, and editing. The business plan is not only an internal company tool for thinking about the 
future, it is also about presenting the company’s idea, solution, marketing strategy, financial pro-
jections, and long-term vision to prospective investors. It is an introspective exercise that each 
executive team should utilize to help identify misconceptions before they become costly, to 
organize and streamline team members’ efforts, to focus on the big picture rather than getting 
caught up in short-term actions, and to establish performance standards for the company 
(Valentin). It is important that all key stakeholders participate in the development and writing of 
the business plan. As the money at risk increases, the benefits of having a well-developed business 
plan increase as well. 
Resources 
1. U.S. Small Business Administration: https://www.sba.gov/business-guide/plan-your-
business/write-your-business-plan 
2. BPlans, produced by Palo Alto Software, is a free resource for new entrepreneurs with 
tools, webinars, and templates for writing a business plan: 
https://articles.bplans.com/writing-a-business-plan/ 
3. Business Plan for Scientists: http://biobm.com/2011/06/business-plans-for-life-scientist-
inventors/ 
4. Business Plans Handbook:  Craft, D. Business Plans Handbook, vol. 42, pp. vii–viii. 
Gale, 2018. Gale Virtual Reference Library, 
https://www.cengage.com/search/productOverview.do?N=197&Ntk=P_EPI&Ntt=20989
37891178320389920751253801030828154&Ntx=mode%2Bmatchallpartial 
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